The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss from continuing operations | -1,127 |
| Stock-based compensation | 28,955 |
| Depreciation and amortization | 3,288 |
| Amortization of deferred contract costs | 1,626 |
| Amortization of debt discount and issuance costs | 0 |
| Amortization of operating lease right-of-use assets | 531 |
| Accelerated amortization of right-of-use asset in connection with lease abandonment | 0 |
| Gain on conversion of note receivable to investment in equity securities | -825 |
| Gain on investment in equity securities | 16,580 |
| Loss on extinguishment of debt | 0 |
| Gain on sale of insurance business | 0 |
| Other | 312 |
| Trade and other receivables | -5,760 |
| Prepaid expenses and other assets, current and non-current | 5,430 |
| Deferred contract costs, non-current | 557 |
| Accounts payable | 206 |
| Deferred revenue | -627 |
| Accrued compensation | 807 |
| Operating lease liabilities | -2,769 |
| Other liabilities, current and non-current | 1,452 |
| Net cash provided by (used in) operating activities - continuing operations | 14,398 |
| Net cash used in operating activities - discontinued operations | -2,886 |
| Net cash provided by (used in) operating activities | 11,512 |
| Purchases of marketable securities | 35,485 |
| Sale of available-for-sale securities | 20,827 |
| Maturities of marketable securities | 46,727 |
| Additions to property, equipment and internal-use software development costs | 11,593 |
| Proceeds from sale of insurance business | 0 |
| Cash received in connection with conversion of note receivable to investment in equity securities | 2,255 |
| Investment in non-marketable equity securities | 4,000 |
| Investment in note receivable | 0 |
| Other | 0 |
| Net cash provided by investing activities - continuing operations | 18,731 |
| Net cash used in investing activities - discontinued operations | -195 |
| Net cash provided by investing activities | 18,536 |
| Proceeds from exercises of stock options, including early exercises, net of repurchases | 1,652 |
| Taxes paid related to net share settlement of equity awards | 9,369 |
| Share repurchases | 24,870 |
| Repayment of long-term debt | 0 |
| Net proceeds from the issuance of the series a redeemable convertible preferred stock and the haveli warrant | 0 |
| Payment for issuance costs related to the series a redeemable convertible preferred stock and the haveli warrant | 0 |
| Net cash used in financing activities - continuing operations | -32,587 |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | 0 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -2,539 |
| Cash, cash equivalents, and restricted cash at beginning of period | 49,537 |
| Cash, cash equivalents, and restricted cash at end of period | 46,998 |
| Less cash, cash equivalents and restricted cash included in current assets held for sale from discontinued operations | 3,420 |
| Cash, cash equivalents and restricted cash, end of period, excluding current assets held for sale from discontinued operations | 43,578 |
Blend Labs, Inc. (BLND)
Blend Labs, Inc. (BLND)